鼻咽癌患者血循环Fas配基的临床意义

刘陶文, 陈煌基

刘陶文, 陈煌基. 鼻咽癌患者血循环Fas配基的临床意义[J]. 中国肿瘤临床, 2004, 31(23): 1360-1361.
引用本文: 刘陶文, 陈煌基. 鼻咽癌患者血循环Fas配基的临床意义[J]. 中国肿瘤临床, 2004, 31(23): 1360-1361.

鼻咽癌患者血循环Fas配基的临床意义

详细信息
  • 中图分类号: R739.62

  • 摘要: Fas配基(Fas Ligand, FasL)属于肿瘤坏死因子 (TNF)家族的!型跨膜糖蛋白,系Fas (Apo-1, CD95)受体的配基。正常情况下,FasL仅表达于活化 的T细胞和自然杀伤(NK)细胞以及眼睛、大脑、睾 丸、胎盘等几个特定免疫赦免部位。有研究报道,一些恶性肿瘤细胞构成性地存在FasL可直接影响其生物学行为。膜结合型FasL可被特定的基质金 属蛋白酶裂解脱落而产生可溶性的FasL (Soluble FasL,sFasL。血清sFasL含量增加与肿瘤的进展及机体的强烈免疫排斥反应有关。有关鼻咽癌 (Nasopharyngeal carcinoma,NPC)患者血循环 sFasL 的含量未见报道。因此,我们观察了一组NPC患者的血清sFasL水平,并分析其临床价值。
  • [1] 1. Younes M, Schwartz MR, Ertan A, et al. Fas ligand expression in esophageal carcinomas and their lymph node metastases[J]. Cancer, 2000, 88(3):524-528.
    2. Song E, Chen J, Ouyang N, et al. Soluble Fas ligand released by colon adenocarcinoma cells induces host lymphocyte apoptosis: an active mode of immune evasion in colon cancer [J], Br J Cancer, 2001, 85(7):1047-1054.
    3. Mitsaides N, Yu WH, Poulaki V, et al. Matrix metalloproteinase— 7 —mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity [J], Cancer Res, 2001, 61(2): 577-581.
    4. Das H, Imoto S, Murayama T, et al. Levels of soluble FasL and FasL gene expression during the development of graft—versus — host disease in DLT—treated patients[J]. Br J Haematol, 1999, 104.(4):795-800.
    5. Tsutsumi S, Kuwano H, Shimura T, et al. Circulating soluble Fas ligand in patients with gastric carcinoma[J]. Cancer, 2000, 89(12): 2560-2564.
    6. Mizutani Y, Hongo F, Sato N, et al. Significance of serum soluble Fas ligand in patients with bladder carcinoma[J]. Cancer, 2001, 92 (2):287-293.
    7. Hsieh MH, Korngold R. Differential use of FasL and perforin— mediated cytolytic mechanisms by T —cell subsets involved in graft—versus—myeloid leukemia responses [J]. Blood, 2000, 96(3): 1047-1055.
    8. Zeytum A, Nagarkatti M, Nagarkatti PS. Growth of FasL—bearing tumor cells in syngeneic murine host induces apoptosis and toxici -ty in Fas+organs[J]. Blood, 2000, 95(6):2111-2117.
    9. Schneider P, Holler N, Bodmer JJL, et al. Conversion of mem-brance—bound Fas (CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity[f].JExpMed, 1998, 187(8):1205-1213.
    10. LiuJH, Wei S, Lamy T, et al. Chronic neutropenia mediated by Fas ligand[J]. Blood, 2000, 95(10):3219-3222.
    11. 刘陶文,黎金庆,廖东,等.急性白血病患者血清中可溶性Fas配基含量的变化田.实用癌症杂志,2002,17(1):48-50.
    12. Martinez—Lorenzo MJ, Anel A, Gamen S, et al. Activated human T cells release bioactive Fas ligand and Apo 2 ligand in microvesi-cles[J].JImmunol, 1998, 163(3):1274-1281.
计量
  • 文章访问数:  4
  • HTML全文浏览量:  0
  • PDF下载量:  1
  • 被引次数: 0
出版历程
  • 收稿日期:  2004-05-16
  • 修回日期:  2004-07-21
  • 发布日期:  2004-12-14

目录

    /

    返回文章
    返回